GLSI

NASDAQ open

Greenwich LifeSciences

19.50 USD
▼-0.29-1.47%
盘后 14.88 0.00%
2026-11-20
市值
$282.56M
市盈率
—
EPS
-1.70
股息率
—
52 周区间
7.78 – 34.10
成交量
87.50K
Beta
1.55
目标价
57.50
52W 低 7.7852W 高 34.10
价格走势

公司简介

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSc...